Sign Up Today and Learn More About Medable Stock
Invest in or calculate the value of your shares in Medable or other pre-IPO companies through EquityZen's platform.
Medable Stock
Medable is transforming clinical research and predictive medicine by creating a platform powered by patient generated data.
About Medable Stock
Founded
2015
Headquarters
Palo Alto, CA, US
Industries
Health Care, Information Technology, Internet Services
Medable provides a global decentralized trial platform that streamlines design, recruitment, retention, and data quality, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. The platform connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. It is now used by leading biopharma sponsors and clinical research organizations worldwide and has been used for trials in 30+ countries and 26 languages. It was founded in 2015 and is headquartered in Palo Alto, California.
Medable Press Mentions
Stay in the know about the latest news on Medable
Medable launches Medable Studio, an all-in-one software solution
fiercebiotech • Aug 15, 2024
Medable, Masimo Partner on Wearable Devices for Clinical Research
mpo-mag • May 29, 2024
Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines By 50%
businesswire • Jan 08, 2024
Medable to Present at 42nd Annual J.P. Morgan Healthcare Conference
biospace • Jan 03, 2024
Medable teams up with Pluto Health to simplify, speed trial recruitment
fiercebiotech • Oct 07, 2023
Medable Management
Leadership team at Medable
Co-Founder & Chief Architect
James Sas
Co-Founder & CEO
Michelle Longmire
Join now and verify your accreditation status to gain access to:
- Medable current valuation
- Medable stock price
- Available deals in Medable and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Medable stock?
Accredited investors can buy pre-IPO stock in companies like Medable through EquityZen funds. These investments are made available by existing Medable shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Medable stock?
Shareholders can sell their Medable stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
